Department of Micro- and Nanotechnology, Technical University of Denmark, Oersteds Plads 345C, 2800 Kgs. Lyngby, Denmark.
School of Pharmacy, University of Otago, Frederick Street 18, Dunedin 9054, New Zealand.
Int J Pharm. 2018 Oct 25;550(1-2):35-44. doi: 10.1016/j.ijpharm.2018.08.036. Epub 2018 Aug 19.
Subunit vaccine formulations are often produced as liquid dispersions through complicated processes. It is desirable, however, to have simple, cheap and up-scalable methods to produce nanoparticulate subunit vaccines in powder form. Here, a simple single-step spray drying process for production of powder cubosome precursors with the model antigen ovalbumin (OVA) and the adjuvant Quil-A is presented. The cubosomes were characterized in vitro and evaluated in vivo by subcutaneous and oral administration for their potential as a vaccine formulation. Hydrated cubosomes had average particle size of 257 ± 8 nm and zeta potential of -18.0 ± 0.6 mV. The powder contained 10.6 ± 0.7% w/w OVA prior to hydration, of which 65 ± 1% was released within the first 20 min in 9.5 mM PBS at pH 7.3, with the remaining OVA gradually released over the following 24 h. Immunization with cubosomes resulted in significantly stronger antigen-specific serum IgG responses (p < 0.01), CD8 T cell expansion (p < 0.0001) and target T cell killing compared to controls when given s.c., and was ineffective orally. This study shows that spray drying is a suitable method for producing nanoparticulate vaccine formulations in dry powder form.
亚单位疫苗制剂通常通过复杂的工艺制成液体分散体。然而,人们希望有一种简单、廉价且可扩展的方法来生产粉末形式的纳米亚单位疫苗。本研究介绍了一种简单的单步喷雾干燥工艺,用于生产包载模型抗原卵清蛋白(OVA)和佐剂 Quil-A 的立方相纳米脂质体前体。对立方相纳米脂质体进行了体外表征,并通过皮下和口服途径进行了体内评价,以评估其作为疫苗制剂的潜力。水合立方相纳米脂质体的平均粒径为 257±8nm,zeta 电位为-18.0±0.6mV。粉末在水合之前含有 10.6±0.7%w/w OVA,其中 65±1%在 pH 7.3 的 9.5mM PBS 中在前 20 分钟内释放,其余 OVA 在随后的 24 小时内逐渐释放。与对照组相比,当通过皮下途径给予立方相纳米脂质体时,可显著增强抗原特异性血清 IgG 应答(p<0.01)、CD8 T 细胞扩增(p<0.0001)和靶 T 细胞杀伤,而口服途径则无效。本研究表明,喷雾干燥是一种适用于生产干粉形式的纳米疫苗制剂的方法。